Related Experiment Video
Updated: May 26, 2026

Left Atrial Ligation in the Avian Embryo as a Model for Altered Hemodynamic Loading During Early Vascular Development
Published on: June 16, 2023
Hypoplastic left heart syndrome: current considerations and expectations
Jeffrey A Feinstein1, D Woodrow Benson, Anne M Dubin
1Department of Pediatrics, Stanford University School of Medicine, Lucile Salter Packard Children's Hospital, Palo Alto, California 94304, USA. jeff.feinstein@stanford.edu
Insights
Hypoplastic Left Heart Syndrome (HLHS) management has dramatically improved, with 70% of newborns now expected to reach adulthood. This paper details the current state of HLHS care across all stages.
Area of Science:
- Pediatric Cardiology
- Congenital Heart Disease
- Neonatal Care
Background:
- Hypoplastic Left Heart Syndrome (HLHS) is a severe congenital heart defect with historically poor outcomes.
- Significant advancements in diagnosis and treatment have transformed HLHS management and survival rates.
- Current survival expectations indicate that approximately 70% of newborns with HLHS may reach adulthood.
Purpose of the Study:
- To present the current state of the art in understanding and treating Hypoplastic Left Heart Syndrome (HLHS).
- To outline the comprehensive management strategies across all stages of HLHS care.
- To address critical aspects including genetics, developmental outcomes, and quality of life for HLHS patients.
Main Methods:
- Review of current diagnostic approaches and management strategies for HLHS.
- Detailed description of the multi-stage treatment protocol: pre-Stage I, Stage I, Stage II, and Stage III (Fontan surgery).
- Inclusion of long-term follow-up considerations, genetics, developmental outcomes, and quality of life.
Main Results:
- Survival rates to age 5 have improved, with expectations for 70% of newborns with HLHS to reach adulthood.
- A well-established 3-stage treatment approach exists, though center-specific variations are noted.
- Comprehensive care strategies encompass fetal assessment through long-term follow-up.
Conclusions:
- Hypoplastic Left Heart Syndrome (HLHS) management has seen a dramatic positive shift in outcomes.
- A standardized, multi-stage approach is crucial for optimizing HLHS patient care.
- Holistic management, including genetics and quality of life, is essential for complex HLHS patients.
Abstract:
In the recent era, no congenital heart defect has undergone a more dramatic change in diagnostic approach, management, and outcomes than hypoplastic left heart syndrome (HLHS). During this time, survival to the age of 5 years (including Fontan) has ranged from 50% to 69%, but current expectations are that 70% of newborns born today with HLHS may reach adulthood. Although the 3-stage treatment approach to HLHS is now well founded, there is significant variation among centers. In this white paper, we present the current state of the art in our understanding and treatment of HLHS during the stages of care: 1) pre-Stage I: fetal and neonatal assessment and management; 2) Stage I: perioperative care, interstage monitoring, and management strategies; 3) Stage II: surgeries; 4) Stage III: Fontan surgery; and 5) long-term follow-up. Issues surrounding the genetics of HLHS, developmental outcomes, and quality of life are addressed in addition to the many other considerations for caring for this group of complex patients.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure V: Medical Management
Cardiomyopathy VI: Nursing Management

